Donna M Edwards, Laila A Gharzai, Weilin Wang, Charles Mayo, Krithika Suresh, Matthew Schipper, Joseph R Evans, Kelly Malloy, Steven B Chinn, Mark Prince, Matthew Spector, Andrew Shuman, Chaz Stucken, Paul L Swiecicki, Francis Worden, Jennifer Jarema, Caitlin Henderson, Amanda Kovach, Chad Brenner, Jennifer L Shah, Michelle L Mierzwa, Keith Casper
BACKGROUND: Post-treatment surveillance recommendations for oropharyngeal cancer do not vary with p16 status despite the differences in outcomes. The optimal algorithm personalizing follow-up for these patients remains undefined. Here, we evaluate the feasibility and utility of incorporating electronic patient-reported outcomes (ePROs) and circulating tumor DNA (ctDNA) into routine surveillance for patients treated for p16+ oropharynx cancer. METHODS: A prospective registry was developed in which ePROs and ctDNA were incorporated into routine surveillance among patients with oropharynx cancer...
April 29, 2024: Head & Neck